To examine whether response to first treatment with onabotulinumtoxinA is predictive of long-term treatment outcome in patients with neurogenic detrusor overactivity (NDO).
Objective
To examine whether response to first treatment with onabotulinumtoxinA is predictive of long-term treatment outcome in patients with neurogenic detrusor overactivity (NDO).
Patients and Methods
Patients with NDO who were enrolled in a 3-year extension study (after a 52-week phase III study) received onabotulinumtoxinA 'as needed', based on fulfilment of prespecified retreatment criteria. This post hoc analysis included patients who received only the 200-U dose during the phase III and extension studies. Data on mean percent reduction from baseline in urinary incontinence (UI) episodes at week 6 after the first treatment were analysed, and the patients were stratified into three response groups: <50% (group 1; n = 33), 50-74% (group 2; n = 23), and 75-100% (group 3; n = 139). The following were assessed: change from baseline in mean percent UI reduction; proportions of patients who achieved ≥50% and 100% UI reduction after each subsequent treatment, and patients who achieved ≥50% UI reduction after all subsequent treatments; change from baseline in Incontinence Quality of Life (I-QOL) total summary score; and the proportion of patients who achieved or exceeded the minimally important difference (MID; +11 points) in I-QOL score. Adverse events (AEs) were also assessed.
Results
The majority of the patients (83.1%; 162/195) experienced a ≥50% UI reduction after onabotulinumtoxinA treatment 1. Baseline characteristics were largely similar across the groups.
After treatment 1, the mean percent reduction in UI remained consistent in subsequent treatments 2-6 for patients in response group 2 (range: 64.5-83.5%) and group 3 (range: 79.4-88.0%), but increased for those in the low response group (range: 36.3-60.3%). After treatment 1, the proportion of patients who achieved ≥50% reduction in UI episodes was consistent with subsequent treatments 2-6 in group 2 (range: 75.0-100%) and group 3 (range: 87.3-97.1%), but increased in the low response group (range: 48.3-72.7%). Even among those who achieved a low response after treatment 1, 37.9% of patients achieved ≥50% UI reduction in all subsequent treatments. Improvements in I-QOL scores in groups 2 and 3 were consistently 2-3 times the MID. In the low response group, at least 50% of the patients achieved or exceeded the MID with treatments 2-6. AEs were similar across all response groups and consistent across repeated treatments.
Conclusion
Patients with NDO with a ≥50% UI reduction after their first onabotulinumtoxinA treatment continued to experience consistent improvements in UI and quality of life with subsequent treatments over the duration of 4 years. A <50% UI reduction after first treatment did not necessarily predict low response with subsequent treatments. Thus, these results underscore the importance of attempting at least a second treatment with onabotulinumtoxinA before deeming patients unsuitable for onabotulinumtoxinA therapy.
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Introduction
Neurogenic detrusor overactivity (NDO) with urinary incontinence (UI) is a common consequence of neural insult attributable to various neurological conditions, including multiple sclerosis and spinal cord injury [1] . Although anticholinergics are often the first line of pharmacological treatment for UI resulting from NDO, their chronic use is limited by insufficient efficacy and intolerable side effects [2] .
OnabotulinumtoxinA 200U is approved for the treatment of UI resulting from NDO in patients who are inadequately managed by ≥1 anticholinergic agent [3] . This approval is based on the results of two 52-week, phase III, randomized, multinational studies in patients with NDO, which showed that onabotulinumtoxinA 200U significantly improved UI, urodynamic outcomes and quality of life (QoL) compared with placebo [4, 5] . Furthermore, these improvements were consistent and unaffected by aetiology or anticholinergic use [6] . The long-term efficacy of onabotulinumtoxinA treatment was also established in this patient population in a prospective, 3-year, multicentre extension study, which showed sustained, clinically meaningful improvements in urinary symptoms and QoL [7] .
Given the high burden of chronic UI caused by NDO [8] and the resulting need for long-term therapy that is durable and effective, it is important to determine if early response to treatment is related to long-term outcomes. Although previous studies have documented the clinically meaningful and durable response with multiple injections of onabotulinumtoxinA in patients with NDO, none have examined the influence of initial treatment response on longterm treatment efficacy and durability. This post hoc analysis assessed whether the long-term response to treatment with onabotulinumtoxinA can be predicted in subsets of patients with NDO, stratified by initial clinical response to treatment.
Patients and Methods

Study Design
Details on the present extension study (ClinicalTrials.gov identifier: NCT00876447) have been published previously [7] . Briefly, patients who completed either of the two 52-week, phase III studies (NCT00311376 and NCT00461292) [4, 5] were eligible to enrol in the extension trial. The enrolled patients had NDO as a result of multiple sclerosis or spinal cord injury and were inadequately managed by ≥1 anticholinergic agent. Patients could have received up to two treatments with onabotulinumtoxinA 200U (approved dose for the treatment of UI attributable to NDO) or 300U administered as 30 1-mL detrusor injections via cystoscopy (sparing the trigone) in the phase III studies, followed by the option of multiple treatments with onabotulinumtoxinA in the extension study. Patients were eligible to receive repeated treatment with onabotulinumtoxinA if they requested retreatment and fulfilled prespecified retreatment criteria (≥12 weeks since previous treatment and ≥1 UI episode within the 3-day bladder diary). As such, the number of treatments received per patient differed. On enrolment in the extension study, patients initially received the same dose of onabotulinumtoxinA (200U or 300U) that they received in the phase III studies; however, an amendment to the protocol in 2011 (based on regulatory agency approval) required all patients to receive only onabotulinumtoxinA 200U for the remainder of the study. Dosing and results reported in the present study are specific to onabotulinumtoxinA. This formulation is not interchangeable with other botulinum toxin products and units cannot be converted using a dose ratio [9] .
To examine the consistency of treatment response, the present report includes patients who only received the 200-U dose of onabotulinumtoxinA, both in the phase III and the extension studies. The duration of treatment effect was different for each patient. Patients in whom onabotulinumtoxinA had a longer duration of effect received fewer treatments and those with a shorter duration received more treatments during the same study period. Data are reported for up to six treatments because the number of patients who needed more than six treatments was very small; therefore meaningful comparisons could not be made. Data were analysed by percent reduction from baseline in UI episodes at week 6 after the first onabotulinumtoxinA treatment and stratified into three response groups: <50% (group 1 or low response group); 50-74% (group 2); and 75-100% (group 3). Baseline was defined as the last UI value before receiving any treatment in the phase III studies.
Efficacy and Safety Assessments
Outcomes assessed in the three response subgroups were mean percent change from baseline in UI episodes/day after each treatment (i.e. after treatments 2, 3, 4, 5 and 6) and proportion of patients who achieved ≥50% and 100% UI reduction with each treatment. The subgroups were also assessed for the proportion of patients who achieved ≥50% UI reduction in all subsequent treatments after treatment 1. Patient-reported outcomes were change from baseline in Incontinence Quality of Life (I-QOL) total summary score [10] and the proportion of patients who achieved or exceeded the minimally important difference (MID; defined as +11 points in NDO) [11] in I-QOL score. Safety assessments included treatment-emergent adverse events (TEAEs) within the first 12 weeks of each treatment.
Statistical Methods
This was a post hoc analysis of the long-term extension study and had no formal statistical power or calculation for sample size. Patient data from the long-term extension study were integrated with their corresponding data from the preceding phase III studies. Efficacy and safety analyses were conducted on those patients who received ≥1 onabotulinumtoxinA treatment of the 200-U dose in the phase III or extension studies.
Safety analyses were performed on the safety population (all patients who received only the 200-U dose of study drug). TEAEs were assessed using the Medical Dictionary for Regulatory Activities version 16.0. Urological TEAEs (≥5% and >1 patient) were evaluated for each response group and presented by treatment number (1-6).
Results
Patient Disposition
A total of 195 patients received only the 200-U dose of onabotulinumtoxinA throughout the phase III and extension studies. Study discontinuations because of lack of efficacy (three patients [1.5%]) and adverse events (AEs; eight patients [4.1%]) were low ( Fig. 1) .
Efficacy After the First OnabotulinumtoxinA Treatment
The majority of patients (83.1% [162/195] ) achieved a ≥50% reduction from baseline in UI episodes after treatment 1, whereas only 16.9% of patients (33/195) experienced a <50% UI reduction. Based on incontinence reduction after the initial treatment, patients were stratified into the following response groups: <50% UI reduction (group 1; n = 33); 50-74% UI reduction (group 2; n = 23); and 75-100% UI reduction (group 3; n = 139). Baseline characteristics were largely similar across the response groups, with minor differences in aetiology and UI episodes ( Table 1) . The mean percent reduction in daily UI episodes at treatment 1 was À4.9%, 64.4% and 96.0% in response groups 1, 2 and 3, respectively.
Long-term Efficacy by First OnabotulinumtoxinA Treatment Response
After treatment 1, the mean percent reduction in UI remained consistent in subsequent treatments 2-6 for patients in groups 2 and 3, but increased for those in group 1 (i.e. the low response group; Fig. 2A) . Likewise, the proportion of patients with a ≥50% UI reduction remained consistent through subsequent treatments 2-6 for groups 2 and 3, but increased in treatments 2-6 for group 1 (Fig. 2B) . A similar trend was seen with the three response groups for the proportion of patients with 100% UI reduction (Fig. 2C) .
Furthermore, analysis of patients with UI reduction after treatment 1 showed that 61.9% and 84.1% of patients in groups 2 and 3, respectively, achieved ≥50% reduction in UI episodes in all subsequent treatments. Even among those who achieved a low response after treatment 1 (i.e. group 1), 37.9% of patients achieved ≥50% UI reduction in all subsequent treatments (Fig. 2D) .
Long-term, repeated onabotulinumtoxinA treatments resulted in consistent improvements in I-QOL in response groups 2 and 3. For patients in both response groups, the changes from baseline in I-QOL scores at each subsequent treatment were consistently 2-3 times the MID (Fig. 3A) , with high proportions continuing to achieve or exceed the MID after treatments 2-6 (Fig. 3B ). In the low response group 1, the mean change from baseline in I-QOL scores increased after treatment 1 and approached or slightly (Fig. 3A) , with the proportion of patients achieving or exceeding MID increasing from 28.1% with treatment 1 to at least 50% with treatments 2-6 (Fig. 3B ).
Safety Measures
AEs were evaluated for each response group after treatments 1-6 ( Table 2 ). The most common urological AEs were urinary tract infection (UTI), urinary retention and haematuria. Urological AE rates were similar across all response groups and consistent across repeated treatments.
Discussion
The present post hoc analysis in patients with NDO shows that the long-term response to onabotulinumtoxinA can be reasonably predicted in different cohorts of patients based on their initial response to treatment. The majority (83.1%) of the patients had ≥50% reduction in UI episodes after the first onabotulinumtoxinA treatment and continued to experience consistent UI reductions and QoL improvements with subsequent treatments over 4 years. While providing further evidence for the sustained long-term efficacy of repeated onabotulinumtoxinA treatment in NDO patients, this analysis also shows that an initial positive response is generally maintained to the same extent after repeat treatments.
As in other studies with multiple injections of onabotulinumtoxinA [12] , a small proportion of patients Baseline (BL) is prior to receiving any treatment in the phase III studies for all patients entering the extension study with data available at week 6. OnabotA, onabotulinumtoxinA. Table 2 Urological adverse events* (≥5% and >1 patient).
TEAEs, n (%)
Response groups by UI reduction at Treatment 1 (16.9%) in our analysis did not achieve a robust reduction in UI after the initial onabotulinumtoxinA treatment. Notably, the low response to initial onabotulinumtoxinA treatment in this analysis was not necessarily predictive of the long-term treatment response; more than one-third (37.9%) of these patients achieved substantial UI reductions (≥50% reduction) in all subsequent treatments. These results are based on a small number of patients who responded poorly to an initial treatment with onabotulinumtoxinA. Nevertheless, they are important particularly because of the limited guidance on the management of patients who have a poor response to initial treatment with botulinum toxins, and bladder augmentation surgery is the only consensus option [13, 14] . The present findings underscore the importance of attempting at least a second treatment with onabotulinumtoxinA in patients who experience a poor response with initial treatment.
One potential reason for low response after the first treatment (and subsequent robust response) could be the variation in injection techniques from treatment to treatment and variation in injection sites within the bladder wall [15] . Decreased bladder compliance in patients with NDO before treatment has been suggested as a potential predictor of poor response to onabotulinumtoxinA [16] ; however, a previous subanalysis of the onabotulinumtoxinA pooled phase III studies in patients with NDO showed significant improvements in efficacy, regardless of their bladder compliance at baseline [17] . Another reason considered for a low initial treatment response followed by improved efficacy with subsequent treatments could be attributable to a potential increase in the use of concomitant anticholinergic medications; however, it has been reported previously that the improvements with onabotulinumtoxinA in patients with NDO were independent of anticholinergic use [6] . It is unlikely that the initiation of clean intermittent catheterization (CIC) during subsequent onabotulinumtoxinA treatments could have contributed to improved response in patients with a low initial treatment response, given that the CIC use/non-use remained consistent over repeated treatments in this subset of patients: of the 29 patients who achieved a <50% UI reduction and received at least two treatments, only one patient changed CIC status (i.e. initiated CIC after the first treatment but not after subsequent treatments) over the course of repeated treatment. This is consistent with previous findings that suggested that few patients change their CIC status over multiple long-term treatments with onbotulimumtoxinA, and patients are unlikely to initiate de novo CIC with repeat treatments if they did not initiate it during their first onabotulinumtoxinA treatment [7] .
The findings of the present study show that examining the different degrees of initial treatment response to onabotulinumtoxinA may also be applicable in a clinical setting, and may help physicians make informed decisions about long-term treatment options for their patients with chronic UI attributable to NDO. Unlike in other studies with oral therapies for NDO, which have shown poor patient adherence rates because of lack of efficacy/side effects [2, [18] [19] [20] , in this study, few patients discontinued because of inadequate efficacy (1.5%) or AEs (4.1%). Most of the discontinuations were related to the burden typically associated with a long-term study (e.g. personal reasons or patients lost to follow-up). Taken together, these results show that onabotulinumtoxinA should be considered as an effective option for long-term therapy in patients with NDO.
The safety results in this analysis are consistent with previous studies [4, 5, 7] and confirm that onabotulinumtoxinA was well tolerated and had a consistent safety profile over multiple long-term treatments, with no new safety signals. The AEs were largely localized to the urinary tract and routinely managed.
One study limitation is the post hoc nature of this analysis and the inclusion of patients who only received the 200-U dose of onabotulinumtoxinA (patients who initially received the 300-U dose were excluded from this analysis); however, previous analyses in the same patient population showed no significant differences in efficacy between the two doses of onabotulinumtoxinA [4, 5] . In addition, the sample sizes of the treatment 1 response subgroups were small and the results should be interpreted accordingly.
In conclusion, the present analysis shows that patients with UI attributable to NDO who experience ≥50% UI reduction after their first onabotulinumtoxinA treatment continue to experience long-term treatment benefit, with consistent and durable reductions in incontinence and improvements in QoL after each subsequent treatment; however, a <50% UI reduction after the first treatment did not necessarily predict low response with subsequent treatments, as many of these patients proceeded to achieve substantial reductions in incontinence and clinically meaningful QoL improvements, thus emphasizing the importance of attempting at least a second treatment with onabotulinumtoxinA. OnabotulinumtoxinA was well tolerated, with no new safety signals. The results of the present analysis further demonstrate that onabotulinumtoxinA is an effective and predictable long-term treatment option for patients with chronic UI attributable to NDO.
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